Agomelatine is a melatonin analog, developed under the assumption that an abnormal circadian rhythm can contribute to depression. However, this theory remains unproven. Read about its potential uses and side effects in this post.
Disclaimer: Agomelatine is not approved in the United States. The development for the US market was discontinued in October 2011. The major concern was that efficacy had not been sufficiently shown. This drug was approved in Europe in 2009 and Australia in 2010, where it can only be used with a doctor’s prescription. Discuss your symptoms with your doctor. He or she will diagnose and treat your health issues.
What is Agomelatine?
Agomelatine (Valdoxan) was developed as an atypical antidepressant on the basis that abnormal circadian rhythms may contribute to depression. This theory requires further human trials to be adequately verified [R].
A major group of antidepressant drugs is selective serotonin reuptake inhibitors (SSRIs). Unlike SSRIs, agomelatine likely activates melatonin (MT1 and MT2) receptors and blocks the 5-HT2C serotonin receptor [R].
Agomelatine is not approved for use in the United States.
This drug was undergoing several phase III clinical trials in the US. Until late 2011, agomelatine was listed as scheduled for submission to the Food Drug Administration (FDA). However, the development for the US market was discontinued and withdrawn in October 2011, when the latest clinical trial results became available [R].
Mechanism of Action
Agomelatine activates melatonergic M1 and M2 receptors and inhibits serotonergic 5-HT2C receptors [R].
Although agomelatine is molecularly similar to melatonin, it has a longer half-life [R].
The half-life of agomelatine is 2.3 hours, while melatonin has a half-life of 50 minutes. Agomelatine may also bind to melatonin receptors stronger than melatonin [R].
By blocking 5-HT2C receptors on dopaminergic and noradrenergic pathways, agomelatine may elevate dopamine and norepinephrine levels in the brain (in the prefrontal cortex but not in the limbic system). Scientists hypothesize this might improve mood and provide nootropic cognitive enhancement [R].
Researchers also suggest that agomelatine may enhance the number of spontaneously-active neurons and the bursting activity of dopaminergic neurons in the ventral tegmental brain area [R].
Research on Depression & Other Diseases
According to some theories, depression is linked to certain abnormalities in the limbic system (part of the brain involved in emotions and memory) and circadian rhythms. Scientists are researching how the following changes may be linked with depression:
- HPA Axis dysfunction, elevated CRH, elevated cortisol, and “cortisol resistance” in the brain [R].
- Unhealthy sleep habits and circadian rhythm issues that may cause people to stay up later and wake up later [R, R].
- Brain inflammation, gut inflammation, “sickness behavior,” and tryptophan and serotonin production [R].
- Reduced BDNF levels [R].
However, additional high-quality studies are needed to determine how valid these hypotheses and potential biomarkers are. None of them have been confirmed in large-scale studies.
Potential Uses of Agomelatine
Agomelatine is not approved in the United States. Discuss your symptoms with your doctor who should recommend approved medical treatment for your condition.
By stimulating melatonin receptors, agomelatine is hypothesized to resynchronize the circadian rhythm with the external environment. In animal studies, agomelatine restored dysfunctional sleep/wake cycles, represented by an enhanced duration of REM and slow-wave sleep after acute oral administration [R].
In Europe, agomelatine is indicated for the treatment of major depressive episodes in adults [R].
In humans, limited research suggests that adjunctive agomelatine may also be useful in the treatment of acute bipolar depression [R].
One open-label study suggests that agomelatine as monotherapy may improve seasonal affective disorder (SAD). However, larger double-blind, randomized, placebo-controlled trials are still needed to further define the clinical value of agomelatine for SAD [R].
Additionally, current evidence suggests that agomelatine alone may not be effective as a monotherapy for the treatment of unipolar or bipolar depression or schizoaffective depression, likely because of its unique mechanism of action [R].
Clinical studies suggest that agomelatine may be used as an adjunctive treatment for depression-related anxiety symptoms. In clinical trials, agomelatine demonstrated the ability to improve anxiety symptoms of major depression [R].
According to limited clinical research, agomelatine may also improve generalized anxiety disorders (GAD) in people that do not have depression.
In one study (double-blind randomized controlled study) involving over 400 patients over the course of 12 weeks, agomelatine was shown to be as effective as escitalopram in mitigating anxiety symptoms [R].
A couple of other trials had positive results. However, people with GAD frequently have other psychiatric and medical illnesses. Therefore, future studies should explore the effects of agomelatine on anxiety in the real-world, general patient population [R].
Melatonin, serotonin, and norepinephrine play a major role in neuropathic pain disorders. Agomelatine may reduce neuropathic pain in fibromyalgia cases that have previously been unresponsive to medical treatment, possibly by blocking the serotonergic receptor 5-HT2C [R, R].
However, the existing studies had several limitations: small sample sizes, short duration, lacking control groups. Additionally, patients with fibromyalgia have a high prevalence of depressive and anxiety disorders. Therefore, it’s hard to tease apart fibromyalgia improvements from agomelatine due to its antidepressant effects [R].
The effects of agomelatine on BDNF, neurotransmitter balance, bone and muscle health, and inflammation have yet to be determined in large-scale clinical trials.
Therefore, the studies outlined below should guide further research, but we can’t draw any conclusions about additional agomelatine indications and/or uses based on them.
Agomelatine should only be used under medical supervision in countries where it has been approved by the governing regulatory agency.
Effects on BDNF
Ongoing research is exploring whether agomelatine increases BDNF levels in the hippocampus, thereby enhancing the survival of existing neurons and synapses and the growth and production of newly-generated ones [R, R].
Some researchers believe agomelatine may influence long-term behavioral response to stress to mitigate symptoms of mood disorders and physiologically enhance the brain’s ability to cope with stressful situations. Their hypotheses remain unproven [R, R, R].
Other research grounds are looking to determine if agomelatine increases CREB (cAMP response element-binding protein), which is posited to prevent the degenerative effect of environmental stressors on the hippocampus [R, R].
Effects on Neurotransmitter Release
By blocking the serotonergic receptor 5-HT2C, agomelatine likely increases norepinephrine and dopamine release in the frontal cortex. Researchers think this may enhance daytime motivation and help combat the physical and mental effects of mood disorders, though their stance remains poorly researched [R, R].
Effects on Bones and Muscles
High amounts of IL-1β, IL-6, and TNF-α may even weaken bones; the link between these cytokines and osteoporosis, arthritis, bone erosion, cartilage degradation, and even gum disease are being researched [R, R, R, R].
Additionally, scientists are investigating whether agomelatine reduces the levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6 [R].
By suppressing these potentially harmful cytokines, agomelatine would theoretically affect bone health. However, the effects of agomelatine on bone health in humans are unknown [R].
Another potential area of agomelatine research is its effects on muscle strength. Rodents treated with agomelatine showed an increase in muscle strength and density, but clinical data are completely lacking [R, R].
Lipopolysaccharides (LPS) is a bacterial toxin. It may leak into the bloodstream in people with increased gastrointestinal permeability or “leaky gut.” It has been linked with inflammation and metabolic problems like insulin resistance, obesity, diabetes, and heart diseases, though most of these associations remain inconclusive [R].
In rats, agomelatine reduces the inflammatory cytokines IL-1beta and IL-6 induced by LPS. In the same study, agomelatine deactivated NF-kB, a protein that turns on inflammatory responses in the immune system [R].
Side Effects and Dangers of Agomelatine
The possible side effects of agomelatine include [R]:
- Back pain
- Excessive sweating
- Migraines and headaches
Importantly, agomelatine can increase liver enzyme levels and may damage the liver.
During treatment, transaminases should be periodically monitored and treatment discontinued if transaminases exceed three times the upper limit of normal [R].
Doctors should perform liver function tests in all patients before starting treatment. Treatment should not be initiated if transaminases exceed three times the upper limit of normal [R].
Additional enzyme screening should be performed after 3, 6, 12, and 24 weeks. If the dosage is increased, the screening period should restart. A final screening after the treatment is also recommended [R].
The use of agomelatine should be stopped if liver enzyme screening indicates a 3X increase of blood transaminases. Beware of symptoms that may indicate potential liver damage, such as dark urine, light-colored stool, yellowing skin or eyes, stomach pain, or new/worsening fatigue [R].
The data on agomelatine overdose is limited but symptoms of an overdose may include [R]:
In a case report, an individual overdosed on 2,450 mg but was able to recover [R].
Risk of Suicide
As with all antidepressants, there is a potential risk of suicide. People at high risk of suicide should be closely monitored by their physician [R].
Pharmaceutical agomelatine is prescribed (as Valdoxan) in 25 mg tablets, typically taken once daily at bedtime. Dosage may be adjusted to 50 mg (2 x 25 mg tablets) taken at bedtime if agomelatine treatment has no effect after two weeks [R].
Antidepressant treatment using agomelatine typically lasts at least six months [R].
Agomelatine should not be prescribed to elderly people (75+ years) [R].